EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association of BDNF Val66Met polymorphism with clinical severity, cognitive function, and treatment response in schizophrenia

Juwita Saragih, Irwan Saputra, Marty Mawarpury, Endang M. Rahayuningsih

Narra X · 22.07.2026 · 4 (2) · e300

DOI: 10.52225/narrax.v4i2.300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Narra X, online erschienen am 22.07.2026. Verfasst von Juwita Saragih und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The brain-derived neurotrophic factor gene (BDNF) Val66Met polymorphism has been implicated in neuroplasticity, cognitive performance, and variability in antipsychotic treatment response. However, evidence from Indonesian populations, particularly among individuals with schizophrenia from Aceh, remains limited. The aim of this study was to assess the association of BDNF Val66Met polymorphism with clinical symptom severity and cognitive function and to determine its association with clinical and cognitive outcomes after antipsychotic treatment. A prospective cohort study was conducted among Acehnese individuals with schizophrenia. Genotyping was performed using polymerase chain reaction–restriction fragment length polymorphism. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function was assessed using the Montreal Cognitive Assessment–Indonesian version (MoCA-INA) at Day 0, Day 14, and Day 42 post-therapy. Genotype–outcome associations were examined using genotype comparisons and genetic models. A total of 207 individuals with schizophrenia were analyzed. The Val/Met genotype was the most frequent genotype (52.2%), followed by Val/Val (28.0%) and Met/Met (19.8%). Baseline PANSS total score was significantly different across all genetic models, with the lowest symptom severity observed in the Val/Val group. In the dominant model, Met-allele carriers had higher PANSS total scores than Val/Val individuals (p

Zitieren

APA

Saragih, J., Saputra, I., Mawarpury, M., & Rahayuningsih, E. M. (2026). Association of BDNF Val66Met polymorphism with clinical severity, cognitive function, and treatment response in schizophrenia. Narra X, 4(2), e300. https://doi.org/10.52225/narrax.v4i2.300

Vancouver

Saragih J, Saputra I, Mawarpury M, Rahayuningsih EM. Association of BDNF Val66Met polymorphism with clinical severity, cognitive function, and treatment response in schizophrenia. Narra X. 2026;4(2):e300. doi:10.52225/narrax.v4i2.300

BibTeX
@article{Saragih2026,
  author = {Saragih, Juwita and Saputra, Irwan and Mawarpury, Marty and Rahayuningsih, Endang M.},
  title = {Association of BDNF Val66Met polymorphism with clinical severity, cognitive function, and treatment response in schizophrenia},
  journal = {Narra X},
  year = {2026},
  volume = {4},
  number = {2},
  pages = {e300},
  doi = {10.52225/narrax.v4i2.300}
}
Kostenlos starten →